[Corrigendum] The effect of NFATc1 on vascular generation and the possible underlying mechanism in epithelial ovarian carcinoma.

Int J Oncol

Department of PICU, Children's Hospital of Chongqing Medical University, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing 400016, P.R. China.

Published: December 2020

Following the publication of the above article, the authors have realized that some incorrect data were included in Fig. 6 in their paper; essentially, the CXCR2 protein bands that were included in the figure were irrelevant, and data for interleukin‑8 (IL‑8) should have been selected and included in the figure instead. The corrected version of Fig. 6 is shown opposite, now featuring the IL‑8 data. The authors confirm that these errors did not significantly influence either the results or the conclusions in their paper. The authors are grateful to the Editor of International Journal of Oncology for allowing them the opportunity to publish this corrigendum, and apologize to the readership for any inconvenience caused. [the original article was published in International Journal of Oncology 48: 1457‑1466, 2016; DOI: 10.3892/ijo.2016.3355].

Download full-text PDF

Source
http://dx.doi.org/10.3892/ijo.2020.5131DOI Listing

Publication Analysis

Top Keywords

included figure
8
international journal
8
journal oncology
8
[corrigendum] nfatc1
4
nfatc1 vascular
4
vascular generation
4
generation underlying
4
underlying mechanism
4
mechanism epithelial
4
epithelial ovarian
4

Similar Publications

Background: Topical steroids are widely used in dermatology for their anti-inflammatory and immunosuppressive effects, but misuse can cause skin thinning and systemic issues. In Ethiopia, where skin conditions are common, understanding how topical steroids are prescribed and used is essential for ensuring their safe and effective use.

Objective: The study aimed to assess topical steroids' prescription and utilization pattern in Dessie Comprehensive Specialized Hospital (DCSH) from February 1 to May 30, 2024.

View Article and Find Full Text PDF

Biomarkers.

Alzheimers Dement

December 2024

Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada.

Background: Drugs targeting Alzheimer's disease (AD) pathology are likely to be most effective in the presymptomatic stage, where individuals harbor AD pathology but have not manifested symptoms. Neuroimaging approaches can help to identify such individuals, but are costly for population-wide screening. Cost-effective screening is needed to identify those who may benefit from neuroimaging, such as those at risk of developing clinical disease.

View Article and Find Full Text PDF

Background: The ARTS biomarker is a fully automated software container that predicts the presence of arteriolosclerosis based on in-vivo MRI data and demographic features. The present study describes findings from the instrumental and clinical validation of ARTS conducted by the MarkVCID consortium.

Method: Instrumental validation of ARTS involved assessment of inter-rater reliability, test-retest repeatability, and inter-scanner reproducibility.

View Article and Find Full Text PDF

Biomarkers.

Alzheimers Dement

December 2024

NYU Grossman School of Medicine, New York, NY, USA.

Background: The choroid plexus (ChP) plays a vital role in CSF production and waste clearance. While existing imaging studies have established connections between ChP volume changes and age-related neurodegenerative diseases, a comprehensive investigation into the microstructural and vascular changes associated with aging remains insufficient. This study aims to explore ChP changes in normal aging using diffusion and perfusion MRI in the HCP-Aging dataset to enhance our understanding of age-related microstructural and vascular changes in the ChP.

View Article and Find Full Text PDF

Biomarkers.

Alzheimers Dement

December 2024

Roche Diagnostics International AG, Rotkreuz, Zug, Switzerland.

Background: Use of neuroimaging [e.g. magnetic resonance imaging (MRI), positron emission tomography (PET), or computed tomography (CT) scan], cerebrospinal fluid (CSF), and blood biomarker tests can contribute to a more accurate and earlier diagnosis of Alzheimer's disease (AD).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!